• WuXi AppTec annual report for 2025 flagged record operating performance, supported by stronger execution of its integrated CRDMO model.
• Order backlog for continuing operations reached RMB 58 billion, up 28.8% year on year.
• Management sharpened strategic focus on core CRDMO operations, targeting faster global capacity buildout to support demand.
• Business mix continued to tilt toward later-stage clinical development, commercial manufacturing, small molecules, TIDES programs.
• Company outlook called for 2026 total revenue of RMB 51.3-53 billion, implying 18%-22% year-on-year growth in continuing operations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. WuXi AppTec Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260401-12090638), on April 01, 2026, and is solely responsible for the information contained therein.